almagate has been researched along with Recrudescence in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Díaz-Llopis, M; Francés, E; Gallego-Pinazo, R; Gómez-Maestra, M; López-Lizcano, R; Udaondo, P | 1 |
| Edmeades, N; Hornan, D; Khan, J; Krishnan, R; Lochhead, J | 1 |
| Kirchhof, B; Pauleikhoff, D | 1 |
3 other study(ies) available for almagate and Recrudescence
| Article | Year |
|---|---|
[Macular thickness might be a recurrence probability predictor in macular edema due to retinal vein occlusions treated with repeated intravitreal injections of antiangiogenics].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Drug Monitoring; Humans; Injections; Macula Lutea; Macular Edema; Prognosis; Ranibizumab; Recurrence; Retinal Vein Occlusion; Vitreous Body | 2009 |
Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Follow-Up Studies; Humans; Intravitreal Injections; Male; Middle Aged; Preoperative Care; Prospective Studies; Recurrence; Visual Acuity; Vitreous Hemorrhage | 2010 |
Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of "lesion activity".
Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Decision Trees; European Union; Exudates and Transudates; Humans; Macular Degeneration; Practice Guidelines as Topic; Ranibizumab; Recurrence; Retreatment; Vascular Endothelial Growth Factor A; Visual Acuity | 2011 |